Truist Securities Starts Dianthus Therapeutics (DNTH) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall Street set to open lower as high-stakes Iran, inflation tests loom
- Oil falls ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook
- Hungarian Gripen jet crashes, no injuries reported, PM Magyar says
- Wall Street set to open lower as high-stakes Iran, inflation tests loom
Guggenheim on Dianthus (DNTH) and Leads BioLabs Deal: 'We view this as a well-structured deal'
October 16, 2025 9:56 AM EDTGuggenheim analyst Yatin Suneja reiterated a Buy rating and $100.00 price target on Dianthus Therapeutics (NASDAQ: DNTH).
The analyst comments "Today, DNTH announced an exclusive global (ex-Greater China) license agreement with Leads Biolabs (HKG: 9887) for DNTH-212, a first-in-class bifunctional BDCA2 and BAFF/APRIL inhibitor, designed to modulate both innate and... More
